HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 100.00% from the company’s current price.

A number of other research analysts have also weighed in on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Tuesday, January 21st. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday.

Evolus Trading Down 4.7 %

NASDAQ EOLS opened at $13.50 on Wednesday. Evolus has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a 50 day simple moving average of $12.85 and a two-hundred day simple moving average of $14.08. The stock has a market cap of $854.83 million, a P/E ratio of -14.84 and a beta of 1.33.

Institutional Trading of Evolus

A number of institutional investors and hedge funds have recently modified their holdings of the business. Tang Capital Management LLC increased its holdings in shares of Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock worth $55,171,000 after purchasing an additional 150,000 shares in the last quarter. Nantahala Capital Management LLC grew its holdings in shares of Evolus by 10.8% in the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock worth $34,557,000 after acquiring an additional 305,300 shares during the period. Caligan Partners LP grew its holdings in shares of Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock worth $29,724,000 after acquiring an additional 498,900 shares during the period. Millennium Management LLC grew its holdings in shares of Evolus by 29.1% in the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock worth $15,107,000 after acquiring an additional 308,753 shares during the period. Finally, Boothbay Fund Management LLC grew its holdings in shares of Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock worth $14,217,000 after acquiring an additional 304,065 shares during the period. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.